References


Contact Points

Dr. Nicola Barlow  
Principal Clinical Scientist  
0121 507 5205  
Email: nicola.barlow1@nhs.net

Mr. Pervaz Mohammed  
Principal Clinical Scientist  
Tel: 0121 507 6077  
Email: pervaz.mohammed@nhs.net

Laboratory  
Tel: 0121 507 5347

Mailing Address  
Department of Clinical Biochemistry  
City Hospital  
Dudley Road  
Birmingham  
B18 7QH

Fax  
0121 507 5290

A PDF copy of this leaflet can be downloaded from our website.  
www.cityassays.org.uk
**Sending Specimens for Analysis**

**Sample requirements:** 0.5 mL of serum can be used for both infliximab drug levels and anti-infliximab antibody analysis.

- The clotted blood sample should be separated within 4 hours of collection.
- Please store serum at −20 °C prior to dispatch. Samples may be sent at ambient temperature by first class post to the address on the back of this leaflet.
- Separated serum is stable for 3 days at room temperature and at least 5 days at 4 °C.
- To aid interpretation of results, it is essential that the following information is included on the request form:
  - Infusion dosing interval
  - Number of infusions to date
  - Reason for request, i.e., poor response
  - Primary diagnosis

**Sample timing**

A TROUGH level sample should be taken just before the next infusion is given (minimum of 6 weeks post previous infusion). To allow steady state concentrations of infliximab to establish, it is advised that samples are only collected from patients on maintenance infliximab therapy.

---

**City Hospital Infliximab TDM Service**

**Infliximab TDM testing strategy**

Our current strategy is that all samples for Infliximab TDM will be first analysed for infliximab drug levels. If the infliximab levels are below the therapeutic cut-off of 1 µg/mL, the sample will go on to have anti-infliximab antibodies measured.

**Serum infliximab assay**

We measure serum infliximab using an in-house ELISA method. The between batch CV’s are: <5 % at the lower reporting limit, <6 % at 1.5 µg/mL and <8 % at 4.0 µg/mL. The assay has been validated against a commercial kit. Our assay measures total infliximab levels (bound and unbound), which is unaffected by TNF-α concentrations.

**Therapeutic ranges**

We suggest a cut-off for a therapeutic trough infliximab level of >1.0 µg/mL in a patient on maintenance dose infusions.¹

**Reporting range**

Our reporting range is 0.4 - 10.0µg/ml.

**Anti-infliximab antibodies assay**

We test for total anti-infliximab antibodies using a commercial kit. The antibody results are qualitative and are reported as negative or positive.

Measuring total antibodies avoids problems with false negative results in patients with a detectable infliximab concentration.

---

**Infliximab background**

Infliximab (Remicade®), is a chimeric human-mouse monoclonal antibody directed against tumour necrosis factor-alpha (TNF-α), approved for use in the treatment of various chronic inflammatory diseases including rheumatoid arthritis, severe crohn’s disease and ankylosing spondylitis. The drug is administered as an infusion with a dosing interval ranging from 2 to 16 weeks.

Infusion of a standard dose of infliximab leads to highly variable inter-individual serum drug concentrations partly due to the development of anti-infliximab antibodies, which bind to infliximab leading to loss of therapeutic effect. Serum trough drug levels have been shown to correlate with clinical response and duration of effect. Furthermore, infliximab is associated with serious side effects with increasing number of infusions and cost is also a significant issue.

**Indications for therapeutic drug monitoring of infliximab**

The main indication for undertaking infliximab TDM is lack of clinical response to the drug. A trough serum infliximab concentration of < 1 µg/mL, in a patient on maintenance infliximab, indicates sub-therapeutic levels. If anti-infliximab antibodies are present, further drug dose increases / infusion interval decreases are less likely to be effective and a change in drug therapy should be considered. In patients with low levels of infliximab but absent antibodies, a dose increase / infusion interval decrease may improve response and here it may be useful to re-measure the serum infliximab levels prior to the next infusion. Positive anti-infliximab antibodies are also associated with an increased risk of infusion reactions and in such patients, concomitant immunosuppressive therapy to reduce the risk might be considered.